Objective To evaluate the long-term safety (up to 3 years) of treatment with pegloticase in
patients with refractory chronic gout. Methods This open-label extension (OLE) study was …

Objective. So far, few data are available to characterize the flare history of patients with gout.
The objective of this study was to describe the frequency and risk factors of gout flares with …

Background Because of the changing dietary habits of an aging population, hyperuricemia
is frequently found in combination with other metabolic disorders. Longstanding elevation of …

Gout is a common rheumatic disease in humans which is characterized by elevation in
serum uric acid levels, and deposition of uric acid crystals in the joint. Hyperuricaemia is the …

Allopurinol, the first-line drug for serum urate-lowering therapy in gout, is approved by the
US Food and Drug Administration for a dose up to 800 mg/d and is available as a low-cost …

Despite being the most common type of inflammatory arthritis, gout is often poorly managed.
Except for febuxostat and pegloticase, research in new therapeutic agents for the …

Background: Gout is a painful and disabling inflammatory arthritis of increasing prevalence
associated with hyperuricemia and the deposition of monosodium urate crystals in soft …

Background Gout therapy includes xanthine oxidase inhibitors (XOI) and colchicine, which
have both been associated with decreased cardiovascular risk. However, their effects on …

Abstract Background and Objective Physical activity (PA) is considered an important
approach to prevent and treat obesity and hyperuricemia. The purpose of the present study …

Objectives: We sought to examine patients' and providers' views on the treatment of gout to
better understand why management is suboptimal. Methods: In-depth telephone interviews …